Table 2.
Specific Anti-CarPA, their relationship with ACPA, RF and ANA, as well as with clinical characteristics in the CAP48 early RA cohort
| CAP48 cohort (n = 189) | Anti-CaFCS (n = 62) | Anti-CaALB (n = 56) | Anti-CaA1AT (n = 79) | Anti-CaA2M (n = 47) | Anti-CaHPX (n = 73) | Anti-CaTF (n = 19) | |
|---|---|---|---|---|---|---|---|
| Age [years, mean (s.d.)] | 36.1 (9.15) | 37.3 (9.65) | 35.7 (9.07) | 36.1 (9.16) | 35.6 (9.55) | 35.8 (9.36) | 38.6 (8.91) |
| Sex (F) | 151/185a (81.6%) | 50/61a (82%) | 44/54a (81.5%) | 64/75a (85.3%) | 36/46a (78.3%) | 60/70a (85.7%) | 15/18a (83.3%) |
| ACPA+ | 129/188a (68.6%) | 51/62 (82.3%) ** | 42/56 (75%) | 65/78 a (83.3%) *** | 38/47 (80.9%) | 58/73 (79.5%) * | 18/19 (94.7%) ** |
| RF+ | 122/188a (64.9%) | 49/58 a (84.5%) ** | 45/52 a (86.5%) *** | 62/75 a (82.7%) *** | 34/42 a (81%) * | 52/68a (76.5%) | 19/19 (100%) *** |
| ACPA–/RF– | 47/188a (25%) | 6/58a (10.3%) | 7/52a (13.5%) | 8/75a (10.6%) | 7/42a (16.6%) | 10/68a (14.7%) | 0/19 |
| ANA+ | 63/162a (38.9%) | 25/61a (40.9%) | 24/45a (53.3%) | 37/70 a (52.9%) ** | 25/42 a (59.5%) ** | 33/64 a (51.6%) ** | 5/18a (27.8%) |
| CRP [mg/dl; mean (s.d.)] | 1.67 (2.99) | 1.23 (1.78) | 1.25 (1.80) | 1.61 (2.56) | 0.92 (1.25) | 1.49 (2.18) | 1.03 (1.76) |
| Erosive disease (BL) | 46/174a (26.4%) | 14/61a (23%) | 9/52a (17.3%) | 18/74a (24.3%) | 10/46a (24.4%) | 17/69a (24.6%) | 6/19 (31.6%) |
| Smokers (ever) | 41/164a (25%) | 15/54a (27.8%) | 9/48a (18.8%) | 15/67a (22.4%) | 17/44 a (38.6%) * | 11/63a (17.5%) | 6/16a (37.5%) |
| DAS28 BL [mean (s.d.)] | 4.40 (1.33) | 4.34 (1.47) | 4.54 (1.31) | 4.40 (1.29) | 4.43 (1.20) | 4.28 (1.38) | 3.7 (1.03)* |
| SDAI BL [mean (s.d.)] | 23.7 (13.9) | 23.8 (16) | 25.8 (15.1) | 23.7 (14.2) | 23.8 (12.9) | 22.8 (15) | 17 (10)* |
| CDAI BL [mean (s.d.)] | 22.1 (13.4) | 23.4 (15.8) | 24.6 (14.5) | 22.6 (13.4) | 23.8 (12.9) | 21.4 (14.2) | 16 (9.8)* |
| HAQ BL [mean (s.d.)] | 1.11 (0.73) | 1.17 (0.74) | 1.18 (0.80) | 1.12 (0.78) | 1.26 (0.77) | 1.07 (0.81) | 0.74 (0.68)* |
| DAS28 12 mo [mean (s.d.)] | 2.71 (1.20) | 2.67 (1.23) | 2.78 (1.29) | 2.73 (1.15) | 2.76 (1.33) | 2.7 (1.19) | 2.3 (0.78) |
| SDAI 12 mo [mean (s.d.)] | 9.46 (9.99) | 8.73 (9.57) | 10.47 (11.42) | 9.49 (8.82) | 10.57 (11.81) | 9.14 (8.93) | 5.91 (4.74) |
| CDAI 12 mo [mean (s.d.)] | 8.88 (9.76) | 8.27 (9.58) | 9.76 (10.98) | 8.95 (8.39) | 9.77 (11.32) | 8.50 (8.41) | 5.32 (4.6) |
| HAQ 12 mo [mean (s.d.)] | 0.61 (0.66) | 0.65 (0.71) | 0.64 (0.69) | 0.63 (0.64) | 0.80 (0.77)* | 0.57 (0.69) | 0.53 (0.63) |
| ΔDAS28 [mean (s.d.)] | −1.77 (1.59) | −1.77 (1.60) | −1.78 (1.48) | −1.68 (1.34) | −1.71 (1.38) | −1.58 (1.49) | −1.57 (1.31) |
| ΔSDAI [mean (s.d.)] | −14.6 (14.6) | −15.2 (15.3) | −15.34 (14.4) | −14.1 (13.4) | −13.18 (12.2) | −13.69 (14.16) | −11.39 (11.21) |
| ΔCDAI [mean (s.d.)] | −13.5 (13.88) | −14.38 (14.48) | −14.81 (13.65) | −13.17 (13.12) | −13.07 (12) | −13.92 (14.15) | −10.91 (10.86) |
| ΔHAQ [mean (s.d.)] | −0.52 (0.85) | −0.54 (0.88) | −0.51 (0.82) | −0.49 (0.79) | −0.46 (0.95) | −0.48 (0.89) | −0.24 (0.68) |
a
missing values. BL: baseline; DAS28: DAS calculated on 28 joints; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index; 12 mo: 12-month follow-up; Δ: delta (12-month value minus baseline value). *P < 0.05; **P < 0.01; ***P < 0.001; bold values denote statistical significance at the P < 0.05 level.